Strides Pharma Science Limited (STAR) reveals robust FY26 results with a 50% YoY growth in operational PAT and a 21% rise in Ex-US markets.
Glenmark Pharmaceuticals Limited (GLENMARK) launches Vancomycin Hydrochloride for Injection in USA, expanding access to quality, affordable medicines.
Valiant Laboratories Limited (VALIANTLAB) announces its board's in-principle approval to explore restructuring options for achieving synergies.
Gland Pharma Limited (NSE: GLAND) reports record revenues and profitability with 22% YoY growth in Q4 FY26 and 97% PAT growth.
Alembic Pharmaceuticals Limited (APLLTD) Q4 FY26 results show a 4% revenue growth, with significant gains in US Formulation and strong EBITDA margin.
Sai Life Sciences Limited (SAILIFE) reports a 29% revenue increase and a 56% EBITDA rise for FY26, driven by strong execution and strategic investments.
Solara Active Pharma Sciences Limited (NSE: SOLARA) reports strong Q4’26 earnings with 40% YoY growth, driven by robust base business despite challenges in Ibuprofen segment.
Hester Biosciences Limited (HESTERBIO) to announce date for Annual General Meeting and dividend details for FY 2026.
Lupin Limited (LUPIN) inaugurates Atharv Ability, a state-of-the-art neuro-rehabilitation center in Delhi, expanding access to advanced care for neurological disorders.
Caplin Point Laboratories Limited (CAPLIPOINT) secures USFDA approval for Foscarnet Sodium Injection, a significant milestone for its subsidiary Caplin Steriles.